Develop a combinatorial approach to cancer immunotherapy of novel high-impact treatments evaluated in advanced murine tumor models. A main focus is to induce neoantigens in concurrent, and future tumors do treat patients in remission and individuals at high risk of developing cancer. A second and complementary approach Dr. Gilboa’s team is developing to enhance the uptake of the neoantigen-engineered tumor cells by the dendritic cell system by coating the tumor cells in situ with endogenous naturally occurring polyclonal antibodies.

• PubMed full listing